3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
6
Hypoxia
4
Sarcoma
3
Prostatic Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Melanoma
2
Solid Tumors
1
Solid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
dactolisib
2
Everolimus
2
surufatinib
1
spartalizumab
1
pasireotide
1
ganitumab
1
fosbretabulin
1
cixutumumab
1
TH 302
1
PM 00104
1
ONC206
1
Fentanyl
1
CLR1404
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroectodermal Tumors, Primitive
×
TH 302
×
Clear all
NCT01381822
2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1
Unknown
58 enrolled